Health9/10/2025•The Guardian
Wegovy maker Novo Nordisk to cut 9,000 jobs amid increased competition
Novo Nordisk, the Danish pharmaceutical company known for its weight-loss drug Wegovy and diabetes medication Ozempic, has announced plans to cut 9,000 jobs, or 11% of its global workforce. This decision comes amid increasing competition from its US rival, Eli Lilly, whose weight-loss drug Mounjaro has been gaining market share, along with the availability of cheaper generic versions of Wegovy. The company has also faced the threat of targeted US tariffs, leading to a profit warning. This restructuring aims to help Novo Nordisk navigate the challenging market conditions and maintain its competitiveness in the industry.
Source: For the complete article, please visit the original source link below.
